Skip to content
← Back to search

WIPO international registration designating the UK WO0000001937613

Threepoint

Published for oppositionWord
TM

Official representation

Trade mark image

Stored locally from an official UKIPO, EUIPO or WIPO source and matched by the exact registration number.

Official representation of trade mark WO0000001937613 — Threepoint
Official UKIPO journal image · 742 × 118 px

Registration details

Trade mark number
WO0000001937613
WIPO record status
Published for opposition
Filed / designated
7 Jul 2026
Published
25 Sep 2026
International registration valid until
7 Jul 2036 · WIPO update 10 Sep 2026
Category
Individual
Mark type
Word

Owner

Contera Pharma A/S

Nice classes

Official source data

Additional trade mark details

Current Madrid designations
AU, CA, CH, CN, GB, JP, KR, NO, US
International registration valid until
2036-07-07
International registration date
2026-07-07
WIPO office of origin
EM
Representative recorded by WIPO
DE FRIES & TUFEKOVIC IP APS

Nice classification

Goods and services

Wording supplied in the official WIPO ROMARIN update WIPO-20260910.

Class 5

Drugs for medical purposes; medicines for human purposes; pharmaceutical preparations; chemical preparations for pharmaceutical purposes; DNA and RNA for medical purposes; antibiotics; antivirals.

Class 42

Research and development services in the field of pharmaceuticals and drug discovery; development of processes and methods for medical and veterinary purposes; development of preparations for medical and veterinary purposes; scientific research for medical purposes, namely, screening for the identification of drug candidates; development of precision RNA therapeutics; development of tailored RNA-based corrective interventions to target the root causes of serious diseases; research and development of new medical products for others; development and identification of novel druggable sites for pharmacological intervention using a bioinformatic discovery platform in a wet lab; screening services, bioinformatics services and modeling services to harness natural processes and modulate gene expression through platforms to generate optimized small molecules, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs); designing and implementing multiplexed high-throughput assays to screen for small molecules that modulate RNA processing using bioinformatic tools; designing and developing algorithms and thermodynamic models.